BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
Authors: M. Guzmán, M. J. Duarte, C. Blázquez, J. Ravina, M. C. Rosa, I. Galve-Roperh, et al
British Journal of Cancer, 17 July 2006
—
Delta(9)-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we…
Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
Authors: María M. Caffarel, David Sarrió, José Palacios, Manuel Guzmán, Cristina Sánchez
Cancer Research, 1 July 2006
—
It has been proposed that cannabinoids are involved in the control of cell fate. Thus, these compounds can modulate proliferation, differentiation, and survival in different manners depending on the cell type and its physiopathologic context. However, little is known about the…
Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
Authors: Sachin Patel and Cecilia J. Hillard
Journal of Pharmacology and Experimental Therapeutics, July 2006
—
Extracts of Cannabis sativa have been used for their calming and sedative effects for centuries. Recent developments in drug discovery have suggested that modulation of neuronal endogenous cannabinoid signaling systems could represent a novel approach to the treatment of anxie…
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
Authors: Sebastian Walther, Richard Mahlberg, Uta Eichmann, Dieter Kunz
Psychopharmacology, May 2006
—
Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects. The aim of the study was to measure the effect of the cannabinoid dronabinol…
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Authors: A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães
Brazilian journal of medical and biological research, April 2006
—
A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent whi…
Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’.
Authors: Rachel E. Westfall, Patricia A. Janssen, Philippe Lucas, Rielle Capler
Complementary Therapies in Clinical Practice, February 2006
—
A majority of women experience some nausea and/or vomiting during pregnancy. This condition can range from mild nausea to extreme nausea and vomiting, with 1-2% of women suffering from the life-threatening condition hyperemesis gravidarum. Cannabis (Cannabis sativa) may be use…
A molecular link between the active component of marijuana and Alzheimer’s disease pathology.
Authors: Lisa M. Eubanks, Claude J. Rogers, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, Kim D. Janda
Molecular Pharmaceutics, 2006
—
Alzheimer’s disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer’s disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease p…
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.
Authors: D. R. Blake, P. Robson, M. Ho, R. W. Jubb, C. S. McCabe
Rheumatology, January 2006
—
OBJECTIVES: To assess the efficacy of a cannabis-based medicine (CBM) in the treatment of pain due to rheumatoid arthritis (RA). METHODS: We compared a CBM (Sativex) with placebo in a randomized, double-blind, parallel group study in 58 patients over 5 weeks of treatment. The…
Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.
Authors: Kahlid Salim, Udo Schneider, Sumner Burstein, Ludwig Hoy, Matthias Karst
Neuropharmacology, June 2005
—
Preclinical findings on ajulemic acid (AJA) showed analgesic and anti-allodynic effects without psychoactive properties making it an appealing substance for the treatment of pain. A recently published randomized double-blind crossover clinical trial described the pain-reducing…
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.
Authors: C. H. Ashton, P. B. Moore, P. Gallagher, A. H. Young
Journal of Psychopharmacology, May 2005
—
Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of can…
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.
Authors: Angelo Vaccani, Paola Massi, Arianna Colombo, Tiziana Rubino, Daniela Parolaro
British Journal of Pharmacology, April 2005
—
We evaluated the ability of cannabidiol (CBD) to impair the migration of tumor cells stimulated by conditioned medium. CBD caused concentration-dependent inhibition of the migration of U87 glioma cells, quantified in a Boyden chamber. Since these cells express both cannabinoid…
Cardiovascular pharmacology of cannabinoids.
Authors: P. Pacher, S. Bátkai, G. Kunos
Handbook of Experimental Pharmacology, 2005
—
Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in…